Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

Xue-Feng Liu1,2†, Xiao-Dong Zhu1,2†, Long-Hai Feng3, Xiao-Long Li4, Bin Xu1,2, Kang-Shuai Li5, Nan Xiao6, Ming Lei1,2, Hui-Chuan Sun1* and Zhao-You Tang1*

Abstract

Background: Physical activity is known to have anti-cancer effects, including immunomodulatory actions. This study investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 therapy to enhance efficacy in patients with unresectable HCC.

Methods: The physical activity levels of patients with unresectable HCC receiving combined lenvatinib plus anti-PD-1 therapy were recorded by questionnaire. Patients were categorized according to physical activity levels (active vs. sedentary). The primary outcome was overall survival (OS). Secondary outcomes included objective response rate (ORR) and progression-free survival (PFS). A subcutaneous syngeneic HCC model was generated in C57BL/6 mice. Mice were randomized to receive placebo, combined lenvatinib plus anti-PD-1 antibodies or combination therapy plus physical activity. Tumors were measured every 3 days and harvested for immunohistochemistry analysis at 20 mm maximum diameter.

Results: Fifty-nine patients with unresectable HCC were categorized to active (n = 28) or sedentary (n = 31) groups. The active group had higher albumin and des-γ-carboxy prothrombin levels and lower hepatitis B virus load at baseline; other clinical and oncologic characteristics were comparable between the two groups. Patients in the active group had significantly longer OS (HR = 0.220, 95% CI 0.060–0.799) and PFS (HR = 0.158, 95% CI 0.044–0.562) and higher ORR (OR = 4.571, 95% CI 1.482–14.102) than patients in the sedentary group. Regular physical activity was independently associated with OS, PFS and ORR. The mouse model showed that physical activity significantly suppressed tumor growth and prolonged survival of tumor-bearing mice. Furthermore, physical activity inhibited Treg cell infiltration and immune checkpoint expression (including CTLA4, TIGIT and TIM3) induced by long-term combined lenvatinib plus anti-PD-1 therapy, improving efficacy.

Conclusions: Regular physical activity was associated with improved outcomes in unresectable HCC receiving combined lenvatinib plus anti-PD-1 therapy. Physical activity may improve therapeutic efficacy by reprogramming the tumor microenvironment from an immunosuppressive to immunostimulatory phenotype.

*Correspondence: sun.huichuan@zs-hospital.sh.cn; zytang88@163.com
†Xue-Feng Liu and Xiao-Dong Zhu contributed equally to this work
1 Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai 200032, China

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Background**

Primary liver cancer is the fifth most commonly diagnosed cancer and second leading cause of cancer-related death in China [1]. Hepatocellular carcinoma (HCC) represents 75–85% of primary liver cancer and is a major global health problem [2]. The majority of patients with HCC are diagnosed at an advanced stage, resulting in limited treatment options and poor prognosis [3]. Systemic therapy, including sorafenib, lenvatinib, and immune check point blockade (ICB), should be considered in patients with unresectable HCC. However, none of these treatment options have achieved satisfactory efficacy when used as monotherapy in published trials [4–8]. Recently, a phase 1b trial testing the combination of lenvatinib and pembrolizumab has shown encouraging results, with a response rate of 36% reported [9]. Nevertheless, adaptive resistance is still one of the major hindrances for those patients.

Upregulation of alternative immune checkpoints is considered one mechanism underlying adaptive immune resistance [10]. When resistance to anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed cell death ligand 1 (anti-PD-L1) therapy develops, the proportion of T cells expressing alternative immune checkpoints, including cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and T-cell immunoglobulin mucin-3 (TIM3), increases [11, 12]. Regulatory T (Treg) cells play a pivotal role in both maintaining immune homeostasis and tumor immune escape [13]. Moreover, PD-1 blockade significantly enhances the infiltration of immunosuppressive Treg cells, contributing to adaptive resistance to immunotherapy [14]. It is reported that lenvatinib reduces Treg cell infiltration and activates immune pathways, resulting in reprogramming of the tumor microenvironment, which may contribute to improvement of the efficacy of anti-PD-1 therapy [15, 16]. Suppressing the infiltration of Treg cells and alternative immune checkpoints level is therefore an attractive strategy to improve the therapeutic efficacy of combined lenvatinib and anti-PD-1 antibody (Ab) therapy.

Regular physical activity is associated with a lower risk of developing several cancers, including HCC [17, 18]. In addition, physical activity reduces the risk of total deaths and cancer-related deaths in both colon and breast cancer [19–21]. Physical activity may reduce tumor cell proliferation, suppress epithelial-mesenchymal transition (EMT), and promote intra-tumoral perfusion/vascularization [22–24]. Moreover, physical activity elicits anti-cancer effects by reducing systemic inflammation and countering immunosenesence [25, 26]. We hypothesize that physical activity may synergize with combined lenvatinib plus anti-PD-1 therapy through immunomodulatory effects to enhance the therapeutic efficacy of this treatment regimen.

**Methods**

**Patients**

Patients with unresectable HCC treated with combined lenvatinib plus anti-PD-1 antibody at Zhongshan Hospital from June 1, 2018 to September 30, 2020 were included in this retrospective study. Inclusion criteria were as follows: (1) patients met the clinical diagnostic criteria for HCC [27], with or without pathological diagnosis; (2) HCC was unresectable and not suitable for transarterial chemoembolization (TACE); (3) treatment with lenvatinib combined with anti-PD-1 antibody was given as first-line systemic therapy; and, (4) an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were excluded if they: (1) had other malignancies; (2) received previous systemic treatment; (3) had no tumor evaluation after initiation of the combined treatment regimen; (4) had incomplete basic information; (5) were unable to specify physical activity details. This study was approved by the Hospital Research Ethics Committee. Informed consent was obtained from all patients.

**Grouping and measurement of physical activity**

Patients took regular physical activity during combined lenvatinib plus anti-PD-1 treatment were classified into the active group, otherwise they were classified into the sedentary group. Physical activity was measured by questionnaire as previously described [19, 28, 29]. Patients or their immediate family members were questioned by phone survey in December, 2020. They were asked the following questions: (1) Does patient take any leisure time physical activity during pharmacotherapy? (2) What kind of physical activity does patient usually take? (brisk-walk, swimming, ball games, Tai Chi, or other aerobic activity) (3) How many days per week does patient take leisure time activity? (4) What is patient's total leisure time activity (perceived scale: 1–4 = low intensity, 5–6 = moderate, 7–10 = vigorous). The criteria for regular physical activity were based on the American College of Sports Medicine guidelines [30]. Patients were considered to engage in regular physical activity if they met any...
of the following criteria: (1) no less than 5 d·wk\(^{-1}\) of moderate aerobic activity for \(\geq 30\ \text{min}·\text{d}^{-1}\); (2) no less than 3 d·wk\(^{-1}\) of vigorous aerobic activity for \(\geq 30\ \text{min}·\text{d}^{-1}\); (3) no less than 3–5 d·wk\(^{-1}\) of mixed intensity activity for \(\geq 30\ \text{min}·\text{d}^{-1}\); or (4) any of the above before or within 1 month after the initiation of combination therapy until 2 months before death or the phone call.

**Treatment outcomes**

The primary treatment outcome was overall survival (OS). Secondary outcomes included objective response rate (ORR) and progression-free survival (PFS). All outcomes were assessed using magnetic resonance imaging and modified response evaluation criteria in solid tumors (mRECIST) criteria for hepatocellular carcinoma response assessment [31].

**Cells and reagents**

Hepa1-6 cells, derived from the BW7756 tumor in a C57L mouse, were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were cultured in high-glucose Dulbecco's modified eagle medium (DMEM) (BasalMedia Technologies Co., Shanghai, China) supplemented with 10% fetal bovine serum (FBS) (Yeasen Biotechnology Co., Shanghai, China) and 1% penicillin–streptomycin (Yeasen Biotech- nology Co., Shanghai, China) at 37 °C under a 5% CO\(_2\) atmosphere.

Lenvatinib was obtained from Eisai (Ibaraki, Japan). Anti-mouse PD-1 Ab (anti-PD-1 Ab; clone RMP1-14) and mouse isotype control IgG (control IgG; clone 2A3) were purchased from Bio X Cell (West Lebanon, NH, USA).

Primary Abs used for immunohistochemical staining included: anti-CD4 Ab (#25229, CST), anti-CD8α Ab (#98941,CST), anti-Forkhead box protein p3 (Foxp3) Ab (ab253297, Abcam), anti-F4/80 Ab (#70076, CST), anti-CTLA4 Ab (A00020, Boster), anti-T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) Ab (A01962, Boster), anti-TIM3 Ab (ab241332, Abcam) and, anti-V domain-containing Ig suppressor of T-cell activation (VISTA) Ab (#54979, CST).

**Subcutaneous syngeneic mouse model**

A subcutaneous syngeneic HCC model was generated by subcutaneously injecting \(\sim 3\times 10^6\) Hep1-6 cells in 100 μl PBS on the backs of 5–6-week-old female C57BL/6 J mice (Charles River Laboratories) (n = 21). Animals were weighed and tumor volume was assessed every three days. Once the maximum diameters reached 10 mm, animals were randomly assigned to receive combination therapy (lenvatinib plus anti-PD-1 Ab; n = 7), combination therapy plus physical activity (n = 7), or placebo (control, drug vehicle plus mouse isotype IgG; n = 7).

Lenvatinib (dissolved in 3 mM HCl, 10 mg/kg) was administered daily by oral gavage [32]. Anti-PD-1 Ab (200 μg/mouse) was intraperitoneally administered every five days [33]. Physical activity was facilitated by placing running wheels in cages; running distance was recorded by electromagnetic sensors in the combination therapy plus physical activity group. Mice were sacrificed and tumors harvested once tumor maximum diameter reached 20 mm. The study was performed in compliance with guidelines for the use of animals established by the institution ethical committee and the "Tumor induction in mice and rats IACUC Guideline" [34].

**Immunohistochemical staining and analysis**

Immunohistochemical staining was conducted as previously described [35, 36] on tissue microarray. Images were captured using the PANNORAMIC panoramic slice scanner after staining. The Densito quant module in the QuantCenter2.1 analysis software was used to quantify the H-Score (H-SCORE = \(\sum (\text{PI} \times 1)\) = (percentage of cells of weak intensity × 1) + (percentage of cells of moderate intensity × 2) + (percentage of cells of strong intensity × 3), where PI represented the percentage of positive signal pixel area; I represented the coloring intensity).

Tumor viability, defined as the proportion of tumors presenting viable cells in a sample (i.e. excluding necrotic regions or granulation tissue), was assessed on hematoxylin and eosin slides. All analyses were performed by an expert pathologist blinded to the treatment arms.

**Statistical analysis**

All statistical analyses were performed using SPSS (Version 22, Chicago, IL, USA). Continuous variables were compared with the Student's t-test (equal variances assumed) or Wilcoxon rank sum test (equal variances not assumed). Categorical variables were analyzed by Chi-squared test or Fisher exact test. Kaplan–Meier survival analysis with the log-rank test was used to evaluate the associations between various interventions and survival. Univariate and multivariate logistic regression was used to determine factors affecting ORR. Multivariate Cox regression was used to determine variables associated with survival. For the analysis, a p-value < 0.05 in a two-tailed test was considered statistically significant. Graphs were drawn with Graphpad Prism (Version 8.0.2, San Diego, CA, USA).
Results
Baseline characteristics of patients
Fifty-nine patients were eligible for this study. Twenty-eight patients were classified into the active group and 31 into the sedentary group. Up to June 30, 2021, the median follow-up duration was 13 months (range, 3–28 months). The baseline clinical characteristics are summarized in Table 1. Compared to patients in the sedentary group, patients in the active group had higher albumin and des-γ-carboxy prothrombin (DCP) levels and lower hepatitis B virus (HBV) viral load at baseline (P < 0.05). However, the usage of antiviral drugs showed no significant difference between the two groups (0.796). Other clinical characteristics were comparable between the two groups.

With respect to the forms of physical activity performed by patients in the active group, brisk walking was the most common one, accounting for 75.0%. In addition to brisk walk, 4 patients chose jogging (14.3%) and 3 patients chose ball games (3.6%), equipment exercising (3.6%) and swimming (3.6%) respectively (Additional file 2: Table S1).

Regular physical activity was associated with improved OS and PFS
Of the 59 patients, 14 died and 17 experienced tumor progression by the last follow-up. The 1- and 2-year OS rates were 92.7% vs. 67.1% and 77.3% vs. 58.7% in the active group and sedentary group, respectively (P < 0.05, Fig. 1A). The 1-year PFS rate was 82.1% in the active group vs. 23.0% in the sedentary group (P < 0.001, Fig. 1B). The median PFS in the active group was 23 months, longer than that in the sedentary group (6 months, P < 0.001). The results of the univariate analysis are presented in Additional file 3: Table S2. Multivariate Cox regression analysis identified that physical activity was independently associated with improved OS (hazard ratio [HR] = 0.203, 95% confidence interval [CI], 0.052–0.794, P = 0.022) and PFS (HR = 0.158, 95% CI 0.044–0.562, P = 0.004) (Table 2).

Regular physical activity was associated with higher ORR
As of June 30, 2021, the ORR in the active group was 57.1% vs. 22.6% in the sedentary group (P < 0.01, Fig. 1C). The results of the univariate analysis are presented in Additional file 3: Table S1. Univariate and multivariate Logistic regression confirmed that regular physical activity and international normalized ratio (INR) were independently associated with OR in patients treated with combination therapy (odds ratio [OR] = 4.204, 95% CI 2.394–7.401, P < 0.001) (Table 3).

Table 1 Baseline characteristics

| Variables                        | Sedentary group (n = 31) | Active group (n = 28) | P value |
|----------------------------------|--------------------------|-----------------------|---------|
| Age (years), mean ± SD           | 55.9 ± 12.4              | 53.5 ± 8.1            | 0.387   |
| Gender                           |                          |                       |         |
| Male                             | 26 (83.9%)               | 27 (96.4%)            | 0.245   |
| Female                           | 5 (16.1%)                | 1 (3.6%)              |         |
| PS score                         |                          |                       |         |
| 0                                | 12 (38.7%)               | 18 (64.3%)            | 0.050   |
| 1                                | 19 (61.3%)               | 10 (35.7%)            |         |
| Overweight                       |                          |                       |         |
| No                               | 30 (96.8%)               | 26 (92.9%)            | 0.599   |
| Yes                              | 1 (3.2%)                 | 2 (7.1%)              |         |
| Child–Pugh classification        |                          |                       |         |
| A                                | 30 (96.8%)               | 27 (96.4%)            | 1.000   |
| B                                | 1 (3.2%)                 | 1 (3.6%)              |         |
| BCLC stage                       |                          |                       |         |
| A                                | 1 (3.2%)                 | 3 (10.7%)             | 0.520   |
| B                                | 7 (22.6%)                | 6 (21.4%)             |         |
| C                                | 23 (74.2%)               | 19 (67.9%)            |         |
| CNLC stage                       |                          |                       |         |
| I                                | 1 (3.2%)                 | 3 (10.7%)             | 0.520   |
| II                               | 7 (22.6%)                | 6 (21.4%)             |         |
| III                              | 23 (74.2%)               | 19 (67.9%)            |         |
| Tumor size (cm), mean ± SD       | 12.3 ± 5.5               | 10.7 ± 5.8            | 0.351   |
| Extra-hepatic metastasis         |                          |                       |         |
| No                               | 26 (83.9%)               | 21 (75.0%)            | 0.398   |
| Yes                              | 5 (16.1%)                | 7 (25.0%)             |         |
| Macrovascular invasion           |                          |                       |         |
| No                               | 11 (35.5%)               | 14 (50.0%)            | 0.260   |
| Yes                              | 20 (64.5%)               | 14 (50.0%)            |         |
| WBC (× 10⁹/L), mean ± SD         | 5.8 ± 2.0                | 5.7 ± 1.9             | 0.828   |
| NLR, mean ± SD                   | 3.3 ± 1.6                | 2.7 ± 1.2             | 0.124   |
| TB (μmol/L), mean ± SD           | 17.5 ± 9.6               | 16.7 ± 7.6            | 0.753   |
| ALB (g/L), mean ± SD             | 38.5 ± 5.8               | 41.6 ± 4.0            | 0.020   |
| ALT (U/L), mean ± SD             | 42.0 ± 26.3              | 40.8 ± 24.7           | 0.856   |
| AST (U/L), mean ± SD             | 73.7 ± 68.4              | 51.6 ± 34.8           | 0.130   |
| GGT (U/L), mean ± SD             | 234.9 ± 233.9            | 183.3 ± 213.8         | 0.368   |
| INR, mean ± SD                   | 1.2 ± 0.1                | 1.1 ± 0.1             | 0.092   |
| AFP (ng/mL)                      |                          |                       |         |
| < 400                            | 13 (41.9%)               | 11 (39.3%)            | 0.836   |
| ≥ 400                            | 18 (58.1%)               | 17 (60.7%)            |         |
| DCP (mAU/mL)                     |                          |                       |         |
| < 400                            | 3 (9.7%)                 | 10 (35.7%)            | 0.036   |
| ≥ 400                            | 28 (90.3%)               | 18 (64.3%)            |         |
| HBsAg                            |                          |                       |         |
| –                                | 05 (16.1%)               | 6 (21.4%)             | 0.602   |
| +                                | 26 (83.9%)               | 22 (78.6%)            |         |
CI 1.302–13.569, P = 0.016; OR = 0.189, 95% CI 0.036–0.992, P = 0.049, respectively) (Table 2).

Physical activity improved the effect of combination therapy in syngeneic HCC mice
To elucidate why physical activity improved the outcomes of HCC patients treated with combination therapy, we established a subcutaneous syngeneic HCC mouse model. The average running distance per mouse per week in the combination therapy plus physical activity group is shown in Fig. 2A. Compared to the control group, both combination therapy and combination therapy plus physical activity groups had lower tumor burden (P < 0.05 and P < 0.001, respectively; Fig. 2B). Physical activity synergized with combination therapy to further

| Table 2 | Multivariate analysis of the association between baseline factors and treatment outcomes |
|----------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| Variables | No. of patients | Overall survival | Progression-free survival | Objective response |
|           |                  | Multivariate Cox regression | Multivariate Logistic regression | Multivariate Logistic regression |
|           |                  | HR (95% CI) | P value | HR (95% CI) | P value | OR (95% CI) | P value |
| Regular physical activity | | | | | | |
| Yes | 28 | 0.203 | 0.022 | 0.158 | 0.004 | 4.204 | 0.016 |
| No | 31 | (0.052–0.794) | | (0.044–0.562) | | (1.302–13.569) | |
| Macrovacular invasion | | | | | | |
| Yes | 34 | 5.430 | 0.03 | | | |
| No | 25 | (1.183–24.935) | | | | |
| INR | | | | | | |
| > 1.20 | 15 | | | 0.189 | 0.049 | |
| ≤ 1.20 | 44 | | | (0.036–0.992) | | |

CI confidence interval, HR hazard ratio, INR international normalized ratio, OR objective response
improve its inhibitory effect on tumor growth (P < 0.05; Fig. 2B).

Both combination therapy and combination therapy plus physical activity groups showed prolonged survival (time to 20 mm in maximum diameter) of tumor-bearing mice compared to the control group, and mice in the combination therapy plus physical activity group had the longest lifespan (median survival of 15, 30 and 54 days in control, combination therapy and combination therapy plus physical activity groups, respectively, P < 0.001; Fig. 2C).

Finally, tumor viability was assessed to further understand the synergistic effect of physical activity and combination therapy. The combination therapy plus physical activity group had the lowest tumor viability (P < 0.0001 vs. control group and P < 0.01 vs. combination therapy group), followed by the combination therapy group (P < 0.0001 vs. control group) (Fig. 2D).

Mechanism of the synergistic effect of physical activity and combination therapy
To elucidate why physical activity improved the efficacy of combination therapy, immunohistochemical staining of major immune cell populations and alternative immune checkpoints was performed. H-scores were generated to quantitatively analyze expression levels among the three groups. Both combination therapy and combination therapy plus physical activity groups showed increased CD4+ T and Treg cell infiltrations and TIGIT expression compared to the control group (Additional file 1: Fig. S1 & Fig. 3). The combination therapy plus physical activity group had elevated immune cell infiltration, including macrophage and CD8+ T cells, and increased CTLA4 and VISTA expression (Additional file 1: Fig. S1 & Fig. 3). Compared to the combination therapy group, the combination therapy plus physical activity group tended to exhibit reduced infiltration of Treg cells and expression of several immune checkpoints, including TIGIT and TIM3.

Interestingly, we observed that mice receiving short-term (<15 days, n = 3) and long-term (≥15 days, n = 4) combination therapy showed distinct immunophenotypes. Short-term combination therapy had a similar immunophenotype to the control group, while long-term combination therapy exhibited an immunosuppressive phenotype, with increased infiltration of Treg cells and higher levels of alternative immune checkpoints, including CTLA4, TIGIT, TIM3 and VISTA (Fig. 3). However,
the combination therapy plus physical activity group showed reduced infiltration of Treg cells and expression of CTLA4, TIGIT and TIM3 (Fig. 3).

Overall, we observed that physical activity inhibited the infiltration of immune-suppressive Treg cells and the adaptive upregulation of alternative immune checkpoints to enhance the therapeutic efficacy of combination therapy.

Discussion
In this study, we found that regular physical activity was associated with improved outcomes in patients with unresectable HCC receiving combined lenvatinib and anti-PD-1 therapy. Compared with the sedentary population, physically active patients had an approximately 80% lower risk of death and progression and four times greater likelihood of reaching objective response criteria. Considering that patients’ basic general status might influence the intensity and frequency of physical activity, we excluded patients with performance score greater than 2. And multivariate analysis shown that the protective effect of regular physical activity was independent from patients’ basic general status. However, considering the small number of patients choosing physical activities other than brisk walk and the short follow-up period, it was difficult to explore the extent to which different physical activities affect survival. Which form of physical activity provides greater benefit to HCC patients required further research.

Previous treatment may affect the efficacy of physical activity and combination therapy. However, in the present study, lenvatinib plus anti-PD-1 was given as first-line systemic treatment, and only one patient in the active group received TACE before combination therapy. Thus, the effect of previous treatment could be excluded. Ample studies have shown that physically active lifestyles reduce the risk of multiple cancers, including HCC [17, 18, 37]. Following primary treatment, physical

![Fig. 3 Immunohistochemical staining and analysis of subcutaneous tumors. Immunohistochemical staining was conducted on subcutaneous tumor tissue microarray. H-score were calculated to quantify the expression levels of marker proteins. Representative images captured at 40 x. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Foxp3 forkhead box protein p3, CTLA4 cytotoxic T-lymphocyte-associated protein 4, TIGIT T cell immunoreceptor with Ig and ITIM domains, TIM3 T-cell immunoglobulin mucin-3, VISTA V domain-containing Ig suppressor of T-cell activation]
activity has been consistently shown to have positive effects on vigor and vitality, cardiorespiratory fitness, quality of life, depression, anxiety, pain and fatigue; physical activity also reduces the overall risk of death and cancer-related death in cancer survivors [19–21, 38]. During primary treatment with lenvatinib, physical activity might enable patients to receive longer-term treatment through improvement of their physical and psychological condition [38]. Moreover, both physical activity and lenvatinib have immunomodulatory effects [15, 16, 25, 26]. Therefore, physical activity might synergize with lenvatinib to enhance the therapeutic efficacy of anti-PD-1 therapy.

To elucidate the reason why physical activity synergizes with combination therapy, we established a subcutaneously implanted HCC mouse model. Since mice are natural runners [39], running wheels were placed in cages of the combination therapy plus physical activity group to facilitate voluntary running. The mouse model showed that physical activity improved the therapeutic efficacy of combination therapy with retarded tumor growth and prolonged survival, consistent with clinical findings in humans.

We found that both combination therapy and combination therapy plus physical activity were associated with an immunosuppressive tumor microenvironment, which contradicts the findings of previous studies [15, 16]. However, the treatment duration in the present study was much longer (median treatment duration of 30 days) than those reported in previous studies [15, 16]. As short-term and long-term treatments showed distinct immunophenotypes, this may account for the contradictory findings of the present study. It is suggested that the immunostimulatory effect of lenvatinib might decrease with prolonged treatment duration.

Our findings suggest that physical activity enhances combined lenvatinib plus anti-PD-1 therapy by counteracting the immunosuppressive tumor microenvironment induced by long-term treatment. Compared to tumors treated with combination therapy, the addition of physical activity inhibited the infiltration of immunosuppressive Treg cells and the expression of several immune checkpoints, including CTLA4, TIGIT and TIM3, reprogramming the tumor immune microenvironment. Notably, the immunomodulatory function of physical activity during long-term treatment postponed tumor progression and prolonged OS. In addition to the modulation of immune microenvironment, physical activity ameliorates immunosenesence through promoting the secretion of several cytokines by skeletal muscle during physical activity, including IL-6, IL-1ra, IL-1β, IL-8, IL-10, and TNF-α, and with decreased levels of IL-2, and IFN-γ [40]. In general, physical activity has immune-promoting effect, which may facilitate the anti-tumor immune response.

In addition to immunomodulatory effects, physical activity has been associated with other anti-cancer mechanisms. It was reported that physical activity suppressed tumor growth by promoting p53-driven apoptosis [41]. Our previous study found that moderate swimming inhibited liver cancer progression through suppression of transforming growth factor-beta-induced epithelial-mesenchymal transition [23]. It was also reported that exercise promoted a shift towards a more “normalized” tumor microenvironment by improving intra-tumoral perfusion/vascularization [42, 43]. Multiple mechanisms may therefore account for the anti-cancer effects of physical activity.

These findings add to the evidence supporting physical activity as an important lifestyle intervention in patients with cancer. In recent years, multiple international organizations have published physical activity recommendations for patients living with and beyond cancer, including the American Cancer Society [44], the American College of Sports Medicine [45], Cancer Care Ontario [46], and the Clinical Oncology Society of Australia [47], and Exercise and Sports Science Australia [48]. The specific value of physical activity in promoting an enhanced treatment response in patients receiving combination lenvatinib plus anti-PD-1 therapy should be explored further in this context.

Our study is not without limitations. Firstly, the retrospective design of the study may have introduced bias, such as recall bias and confounding bias. Secondly, the sample size of this retrospective study is small. Thus, a well-designed prospective study with large sample size is required to control bias and quantify the physical activity level. Thirdly, the PD-1 inhibitors used in this study was not unified. All PD-1 inhibitors were off-label therapies for HCC and cannot be reimbursed in China, which made patient's choice become an important consideration (mostly cost and updated information from clinical trials). Fourthly, the duration of combination treatment might influence the intra-tumor immunophenotype, which was not accounted for at the time of study conception. Further studies are needed to confirm the effect of duration of combination treatment on the tumor microenvironment.

**Conclusions**
The present study suggests that physical activity improved the therapeutic efficacy of long-term combined lenvatinib plus anti-PD-1 therapy in patients with
HCC through reprogramming the tumor microenvironment from an immunosuppressive to immunostimulatory phenotype. This study provides evidence for recommending physically active lifestyles to patients with unresectable HCC receiving combined lenvatinib and anti-PD-1 therapy.

Abbreviations
- AFP: Alpha-fetoprotein; ALB: albumin; ALT: Alanine transaminase; AST: Aspartate transaminase; ATCC: American Type Culture Collection; BCLC: Barcelona Clinic Liver Cancer; CNLC: China Liver Cancer; CTLA4: Cytotoxic T-lymphocyte-associate transaminase; DMEM: Dulbecco’s; DCP: Des-γ-carboxy prothrombin; GGT: Gamma-glutamyl associated protein 4; ITIM: Immunoreceptor tyrosine-based inhibitory motif; mRECIST: Modified response evaluation criteria in solid tumors; NLR: Neutrophil–lymphocyte ratio; OR: Objective response; ORR: Objective response rate; OS: Overall survival; PD-1: Programmed cell death protein 1; PFS: Progression free survival; PS: Performance status; TACE: Transarterial chemoembolization; TB: Total bilirubin; TIGIT: T-cell immunoreceptor with Ig and ITIM domains; TIM3: T-cell immunoglobulin mucin-3; Treg cells: Regulatory T cells; VISTA: V domain-containing Ig suppressor of T-cell activation; WBC: White blood count.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40164-022-00275-0.

Additional file 1: Figure S1. Immunohistochemical staining and analysis of subcutaneous tumors. Immunohistochemical staining was conducted on subcutaneous tumor tissue microarray. H-score were calculated to quantify the expression levels of marker proteins. Representative images captured at 40X. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Additional file 2: Table S1. Distribution of selected physical activities in the active group.

Additional file 3: Table S2. Univariate analysis of the association between baseline factors and treatment outcomes. AFP alpha-fetoprotein, ALB albumin, ALT alanine transaminase, AST aspartate transaminase, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, CNLC China Liver Cancer, DCP des-γ-carboxy prothrombin, GGT gamma-glutamyl transpeptidase, HBV hepatitis B virus, HBsAg hepatitis B surface antigen, HR hazard ratio, INR international normalized ratio, NLR neutrophil–lymphocyte ratio, OR odds ratio, PS performance status, TB total bilirubin WBC white blood count.

Acknowledgements
Not applicable.

Author contributions
XFL and XDZ conceived the idea, designed the study, collected the data and wrote the initial draft of the paper. LHF and XLL analyzed the data. BX and KSL conducted the immunohistochemical staining of the tissue microarray and analyzed the results. NX and ML interpreted the results. HCS and ZYT conceived the idea, supervised and supported the study and revise the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the Leading Investigator Program of the Shanghai municipal government (17XD140100), the National Key Basic Research Program (973 Program; 2015CB554005) from the Ministry of Science and Technology of China, and the National Natural Science Foundation of China (81672326 and 81871928).

Received: 10 January 2022   Accepted: 29 March 2022
Published online: 04 April 2022

Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Ethical approval was obtained from the Zhongshan Hospital Ethics Committee. Informed consent was obtained from all participants. Animal research was conducted in compliance with guidelines for the use of animals established by the institution ethical committee and the “Tumor induction in mice and rats IACUC Guideline”.

Consent for publication
Not applicable.

Competing interests
HCS has received speaker fees from Hengrui, Bayer, Eisai, and MSD. XDZ has received speaker fees from Eisai and MSD. The other authors declare that they have no competing interests.

Author details
1 Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai 200032, China. 2 Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032, China. 3 Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China. 4 Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China. 5 Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, China. 6 Department of Breast Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

1. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021. https://doi.org/10.1002/cac.212197.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
3. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.
4. Kudo M, Finn RS, Qin S, Han KH, Ikeeda K, Piscaglia F, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
5. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Della Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Grendel TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
7. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B,
Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL. Proliferumbizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Danièle B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M. Proliferumbizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52.

Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AO, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutuc CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib study of lenvatinib plus pembrolizumab in patients with unseetable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–70.

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint target: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

Koyama S, Akbay EA, Yi YY, Herter‑Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson JE, Banne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hamer‑Mansuy J, Franck JW, Fukuoka T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(36):2970–80.

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint target: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

Koyama S, Akbay EA, Yi YY, Herter‑Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson JE, Banne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hamer‑Mansuy J, Franck JW, Fukuoka T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(36):2970–80.

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint target: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

Koyama S, Akbay EA, Yi YY, Herter‑Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson JE, Banne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hamer‑Mansuy J, Franck JW, Fukuoka T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(36):2970–80.

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint target: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

Koyama S, Akbay EA, Yi YY, Herter‑Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson JE, Banne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hamer‑Mansuy J, Franck JW, Fukuoka T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(36):2970–80.
43. McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst. 2014;106(4):dju036.
44. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):243–74.
45. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Grünigen VE, Schwartz AL. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.
46. Segal R, Zwaal C, Green E, Tomaseone JR, Loblaw A, Petrella T. Exercise for people with cancer: a clinical practice guideline. Curr Oncol. 2017;24(1):40–6.
47. Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, McCarthy S, Murnane A, Patchell S, Adams D. Clinical oncology society of Australia position statement on exercise in cancer care. Med J Aust. 2018;209(4):184–7.
48. Hayes SC, Newton RU, Spence RR, Galvão DA. The exercise and sports science Australia position statement: exercise medicine in cancer management. J Sci Med Sport. 2019;22(11):1175–99.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.